AbbVie マネジメント
マネジメント 基準チェック /24
AbbVieの CEO はRobert Michaelで、 Jul2024年に任命され、 の在任期間は 1.75年です。 の年間総報酬は$ 32.53Mで、 5.2%給与と94.8%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.01%を直接所有しており、その価値は$ 36.46M 。経営陣と取締役会の平均在任期間はそれぞれ2年と9.6年です。
主要情報
Robert Michael
最高経営責任者
US$32.5m
報酬総額
| CEO給与比率 | 5.23% |
| CEO在任期間 | 1.8yrs |
| CEOの所有権 | 0.01% |
| 経営陣の平均在職期間 | 2yrs |
| 取締役会の平均在任期間 | 9.6yrs |
経営陣の近況
Recent updates
AbbVie: Balancing Potential Acquisition Impact With Positive Q1 2026 Earnings
Apr 30
ABBV: Future Returns Will Rely On Immunology Expansion And Operating Leverage Execution
Analysts made a small upward adjustment to AbbVie’s fair value estimate to about $249. The modest change reflects a mix of slightly higher assumed discount rates and future P/E multiples, alongside recent shifts in Street price targets, including both raises and trims from firms such as Piper Sandler, Guggenheim, Cantor Fitzgerald, Evercore ISI, Citi and UBS, as well as fresh bullish initiations from Canaccord, RBC Capital and Barclays.ABBV: Future Returns Will Hinge On Immunology Encore And Operating Leverage Execution
Analysts have made a modest upward adjustment to AbbVie’s price target, reflecting updated views on its immunology pipeline potential, operating leverage, and the ongoing debate about whether recent share underperformance and selloffs adequately reflect competitive risks. Analyst Commentary Recent research on AbbVie highlights a split view, with some analysts focusing on the upside from the immunology pipeline and operating leverage, while others point to valuation and competitive questions after a period of share underperformance.ABBV: Future Returns Will Hinge On Immunology Encore Outweighing Competitive Concerns
Narrative Update The analyst price target for AbbVie has been adjusted slightly higher to reflect a fair value move to about $249. Analysts point to early stage indication expansion, operating leverage potential, and ongoing immunology pipeline developments, even as some firms flag emerging competition and a more balanced risk and reward profile.ABBV: Future Returns Will Depend On Immunology Encore And Deal Optionality Uncertainty
The analyst price target for AbbVie edges higher to align with our fair value shift from $248.29 to $248.86, as analysts highlight ongoing indication expansion in immunology, potential operating leverage, and multiple expansion drivers, even as some firms note emerging competition and a more balanced risk and reward profile. Analyst Commentary Recent research on AbbVie reflects a split view, with some analysts pointing to upside tied to immunology growth and pipeline execution, while others flag competition risk and a more balanced risk and reward profile at current levels.
AbbVie Inc. (ABBV): The Immunology Powerhouse – Successfully Navigating the Post-Humira Transition
AbbVie (ABBV) has entered 2026 as a masterclass in pharmaceutical "lifecycle management," having effectively neutralized the long-feared "patent cliff" of its flagship drug, Humira. As of the February 27, 2026 close, the stock is trading at $232.03 , following a robust 3.3% single-day gain that capped off a volatile but ultimately bullish month.ABBV: Future Returns Will Rely On Immunology Encore And Evolving Deal Optionality
Our updated AbbVie narrative reflects a modest price target increase to about $248 per share, as analysts point to potential operating leverage, room for P/E multiple expansion, and a pipeline of proof-of-concept and immunology programs that could support slightly higher revenue growth assumptions, even as margin expectations are trimmed. Analyst Commentary Recent research shows a mix of optimism and caution around AbbVie, with several firms adjusting price targets and ratings as they reassess execution risks, competitive pressures, and the potential impact of the pipeline on valuation.ABBV: Future Returns Will Depend On Immunology Pipeline Clarity And M&A Uncertainty
Analysts have trimmed their price targets for AbbVie by a small amount. This reflects slightly lower revenue growth and P/E assumptions, while also incorporating a modestly higher profit margin and recent mixed research views around competition and pipeline visibility.ABBV: Future Returns Will Hinge On Post-Humira Immunology And Deal Optionality
Analysts have nudged their price target for AbbVie slightly higher to reflect a fair value estimate of about $245 per share, supported by updated assumptions for revenue growth, profit margins, and a modestly lower future P/E. Recent research highlights both increased price targets and more cautious views around competition and the sustainability of outperformance in key immunology drugs.ABBV: Future Returns Will Depend On Post-Humira Immunology And Pipeline Execution
Analysts have trimmed their AbbVie fair value estimate by about $0.10 per share to roughly $244.56. This reflects a mix of slightly higher risk assumptions, modestly adjusted revenue and margin expectations, and a more balanced set of views after recent downgrades and price target changes that suggest outperformance is already well reflected in the current share price.AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
Jan 08
ABBV: Future Returns Will Hinge On Post-Humira Immunology And Pipeline Execution
Analysts have nudged our AbbVie fair value estimate slightly higher, from $243.55 to $244.68. This reflects modestly stronger long term revenue growth expectations for key immunology franchises and pipeline assets, partially offset by slightly lower margin assumptions and a broadly constructive but mixed backdrop of recent price target revisions and rating changes across the Street.ABBV: Future Performance Will Depend On Extended Exclusivity And Pipeline Execution
Analysts have nudged their average price target on AbbVie modestly higher to reflect a wave of target increases into the mid 240s to low 260s dollar range, supported by stronger visibility into Skyrizi and Rinvoq driven growth, extended Rinvoq exclusivity, and a more favorable large cap biopharma backdrop despite mixed ratings changes. Analyst Commentary Recent research paints a generally constructive picture on AbbVie, with most price target revisions skewing higher even as some firms move to the sidelines.AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73
Dec 02ABBV: Future Performance Will Depend On Pipeline Expansion And Patent Protections
AbbVie’s analyst price target has increased modestly from $241.29 to $243.55. Analysts cite resilient performance in immunology products, extended Rinvoq exclusivity, and improving fundamentals as key drivers of sentiment.AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
Nov 18ABBV: Future Performance Will Reflect Balance Between Patent Wins and Product Pressures
AbbVie's analyst price target has risen modestly from $237.48 to $241.29. Analysts cite resilient fundamentals and long-term patent settlements, which help offset recent industry downgrades and softer performance in some business units.Continued Expansion in Neuroscience and Immunology Will Drive Leadership Beyond 2025
AbbVie's analyst price target has been raised from approximately $233 to $237 per share. Analysts cite ongoing revenue growth, improved margins, and extended exclusivity for key products as the main drivers behind the upward revision.Expanding Immunology And Neuroscience Will Reshape Global Healthcare
AbbVie's analyst price target has increased significantly, rising from $227 to $233 per share. Analysts cite recent positive developments in patent settlements and stronger-than-expected performance across key growth drivers as the main rationales.Expanding Immunology And Neuroscience Will Reshape Global Healthcare
AbbVie’s consensus price target has been raised from $217.45 to $227.22, as analysts highlight the value added by the extended Rinvoq patent runway, top- and bottom-line beats, pipeline expansion through the Bretisilocin acquisition, and underappreciated royalty streams. Analyst Commentary Bullish analysts cite a substantial extension of Rinvoq’s U.S. patent runway through favorable settlement, delaying generic entry until 2037—4 years beyond prior expectations—and modeling this as adding $11-$24 per share in value.Expanding Immunology And Neuroscience Will Reshape Global Healthcare
AbbVie's price target was raised to $217.45 as analysts cited the value impact of extended Rinvoq exclusivity from litigation settlement, strong Q2 results, and positive pipeline developments, outweighing near-term Aesthetics headwinds. Analyst Commentary Bullish analysts cite the settlement of litigation regarding generic Rinvoq, extending market exclusivity in the U.S. to 2037 and reducing threats from earlier-than-anticipated generic competition.CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$4b |
| Dec 31 2025 | US$33m | US$2m | US$4b |
| Sep 30 2025 | n/a | n/a | US$2b |
| Jun 30 2025 | n/a | n/a | US$4b |
| Mar 31 2025 | n/a | n/a | US$4b |
| Dec 31 2024 | US$18m | US$2m | US$4b |
| Sep 30 2024 | n/a | n/a | US$5b |
| Jun 30 2024 | n/a | n/a | US$5b |
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$14m | US$1m | US$5b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jun 30 2023 | n/a | n/a | US$9b |
| Mar 31 2023 | n/a | n/a | US$8b |
| Dec 31 2022 | US$10m | US$1m | US$12b |
| Sep 30 2022 | n/a | n/a | US$13b |
| Jun 30 2022 | n/a | n/a | US$13b |
| Mar 31 2022 | n/a | n/a | US$12b |
| Dec 31 2021 | US$12m | US$1m | US$11b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$7b |
| Mar 31 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$13m | US$1m | US$5b |
| Sep 30 2020 | n/a | n/a | US$7b |
| Jun 30 2020 | n/a | n/a | US$7b |
| Mar 31 2020 | n/a | n/a | US$8b |
| Dec 31 2019 | US$9m | US$907k | US$8b |
報酬と市場: Robertの 総報酬 ($USD 32.53M ) は、 US市場 ($USD 14.57M ) の同規模の企業の平均を上回っています。
報酬と収益: Robertの報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。
CEO
Robert Michael (55 yo)
1.8yrs
在職期間
US$32,530,984
報酬
Mr. Robert A. Michael, C.P.A., served as Chief Operating Officer at AbbVie Inc. since June 29, 2023 until July 01, 2024 and served as its President since June 23, 2022 until July 01, 2024 also serves as it...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Chairman of the Board | 1.8yrs | US$32.53m | 0.010% $ 36.5m | |
| Executive VP & CFO | 3.8yrs | US$12.35m | 0.0022% $ 7.9m | |
| Executive VP & COO | 1.8yrs | US$10.79m | 0.012% $ 41.7m | |
| Executive VP of Research & Development and Chief Scientific Officer | 1.8yrs | US$9.91m | 0.0031% $ 11.3m | |
| Executive VP & Chief Commercial Officer | no data | US$15.44m | 0.0048% $ 17.2m | |
| Senior VP & Chief Information Officer | less than a year | データなし | データなし | |
| Senior Vice President of Investor Relations | no data | データなし | データなし | |
| Executive VP | 3.5yrs | データなし | 0.00026% $ 937.6k | |
| Executive VP & Chief Human Resources Officer | 1.3yrs | データなし | 0.00045% $ 1.6m | |
| Senior VP & President of Oncology | 2.5yrs | データなし | データなし | |
| Executive VP and Chief Business & Strategy Officer | 3.3yrs | データなし | 0.0042% $ 15.2m | |
| Senior Vice President of Corporate Affairs | 2.3yrs | データなし | データなし |
2.0yrs
平均在職期間
54yo
平均年齢
経験豊富な経営陣: ABBVの経営陣は 経験豊富 であると考えられます ( 2年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Chairman of the Board | 1.8yrs | US$32.53m | 0.010% $ 36.5m | |
| Lead Independent Director | 13.3yrs | US$432.88k | 0.00065% $ 2.3m | |
| Independent Director | 5.9yrs | US$397.88k | 0.0071% $ 25.5m | |
| Independent Director | 13.3yrs | US$383.44k | 0.0010% $ 3.6m | |
| Independent Director | 13.3yrs | US$382.88k | データなし | |
| Independent Director | 13.3yrs | US$402.88k | 0.00011% $ 396.7k | |
| Independent Director | 8.9yrs | US$407.88k | 0% $ 0 | |
| Independent Director | 10.3yrs | US$397.88k | データなし | |
| Independent Director | 7.9yrs | US$372.88k | データなし | |
| Independent Director | 13.3yrs | US$498.49k | 0.000010% $ 36.1k | |
| Independent Director | 2.5yrs | US$359.51k | 0% $ 0 | |
| Independent Director | 2.5yrs | US$372.88k | 0% $ 0 |
9.6yrs
平均在職期間
67.5yo
平均年齢
経験豊富なボード: ABBVの 取締役会 は 経験豊富 であると考えられます ( 9.6年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/04/30 13:50 |
| 終値 | 2026/04/30 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
AbbVie Inc. 27 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。51
| アナリスト | 機関 |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Luisa Hector | Berenberg |